Please try another search
Kolon TissueGene, Inc. engages in developing cell therapies to target various orthopedic diseases and degenerative disorders. The company develops cell therapies for osteoarthritis, including knee and hip; musculoskeletal system disorder comprising spinal disk; and vet medicine for knee. It also has collaboration with Kolon Life Science, Inc. The company was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. Kolon TissueGene, Inc. was founded in 1999 and is based in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
David Hunter | - | 2016 | Member of Scientific Advisory Board |
Philip G. Conaghan | - | 2017 | Member of Scientific Advisory Board |
Peter Shin | - | - | Member of Business Advisory Board |
Javad Parvizi | - | - | Member of Clinical Advisory Board |
Michael A. Mont | - | - | Member of Clinical Advisory Board |
Jung In Kim | - | 2021 | CFO & Director |
Terry L. Lierman | 74 | - | Member of Business Advisory Board |
Moon-jong Noh | - | 2001 | Co-CEO, Co-President & Director |
Sung Han | - | 2020 | Co-CEO, Co-President & Director |
Ali Mobasheri | - | 2020 | Member of the Scientific Advisory Board |
SunJoo Lee | - | 2023 | Independent Outside Director |
Young J. Kim | - | 2021 | Statutory Auditor & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review